AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

The utility of AsCas12a can be limited to poor editing efficiency. Here the authors identify a variant, “AsCas12a Ultra”, that has high on-target specificity demonstrated through editing of clinically relevant T cell genes.

Saved in:
Bibliographic Details
Main Authors: Liyang Zhang, John A. Zuris, Ramya Viswanathan, Jasmine N. Edelstein, Rolf Turk, Bernice Thommandru, H. Tomas Rube, Steve E. Glenn, Michael A. Collingwood, Nicole M. Bode, Sarah F. Beaudoin, Swarali Lele, Sean N. Scott, Kevin M. Wasko, Steven Sexton, Christopher M. Borges, Mollie S. Schubert, Gavin L. Kurgan, Matthew S. McNeill, Cecilia A. Fernandez, Vic E. Myer, Richard A. Morgan, Mark A. Behlke, Christopher A. Vakulskas
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Science
Q
Online Access:https://doaj.org/article/0168163683a24415a8a5f32e5a19e09a
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items